All In Biotech

Drug Trial Radar · NCT07087795

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

A Study to Investigate Efficacy and Safety of NNC0194-0499 Versus Placebo, Both Administered Alone or in Combination With Semaglutide in People With Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Sep 12, 2026

Study completion Sep 25, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • NNC0194-0499Drug

    Participants will receive subcutaneous NNC0194-0499 once weekly.

  • PlaceboDrug

    Participants will receive placebo matched to NNC0194-0499 subcutaneously.

  • SemaglutideDrug

    Participants will receive subcutaneous semaglutide once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)Time frame: From baseline (day -14 - -1) to day 36-49 / day 106-119
  2. Part B: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL)Time frame: From baseline (day -14 - -1) to day 92-105 / day 162-175

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Institut für Stoffwechselforschung GmbH

    Neuss, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.